Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 9:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–46 of 22 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Mock treatment Clear all
Recruiting Phase 2 Interventional

Supplemental Postoperative Bupivacaine Following Non-Surgical Endodontic Treatment

NCT06655454
View directory record Official record
Conditions
Pain Assessment, Quality of Life (QOL), Analgesic Use
Interventions
Supplemental Postoperative Bupivacaine, Placebo Injection
Drug
Lead sponsor
New York University
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 28, 2026, 9:00 PM EDT
Not listed Phase 1Phase 2 Interventional

Mesenchymal Stem Cell Therapy for Knee Osteoarthritis

NCT05288725
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Bone Marrow Derived MSCs, Corticosteroid, Bone Marrow Aspirate
Biological · Drug · Device
Lead sponsor
Next Generation Regenerative Medicine LLC
Network
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
Chesterfield, Missouri • Steubenville, Ohio • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 20, 2022 · Synced Sep 28, 2026, 9:00 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy

NCT07235085
View directory record Official record
Conditions
Non-Proliferative Diabetic Retinopathy
Interventions
Single intravitreal injection of axitinib hydrogel implant followed by a mock (sham) injection procedure at Week 24, Intravitreal injection of axitinib hydrogel implant followed by a second intravitreal injection of the axitinib implant at Week 24, Sham/mock procedure of intravitreal injection followed by a second sham/mock procedure at Week 24
Drug · Other
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
930 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Hagerstown, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Sep 28, 2026, 9:00 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in Adults (ENLIGHTEN 2)

NCT05295459
View directory record Official record
Conditions
Chronic Sinusitis, Chronic Rhinosinusitis (Diagnosis)
Interventions
LYR-210, Sham procedure control, Background therapy
Drug · Other
Lead sponsor
Lyra Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
31
States / cities
Tucson, Arizona • Arcadia, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Sep 28, 2026, 9:00 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of HF-LED-RL in Fitzpatrick Skin Types I to III

NCT03433222
View directory record Official record
Conditions
Skin Diseases, Keloid, Scar, Fibrosis, Hypertrophic Skin
Interventions
HF-LED-RL Phototherapy, Mock Therapy
Device
Lead sponsor
VA Northern California Health Care System
Federal
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Mather, California
Source: ClinicalTrials.gov public record
Updated Feb 13, 2018 · Synced Sep 28, 2026, 9:00 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Transvaginal Low-level Laser Therapy to Improve Pelvic Pain and Sexual Function in Patients with Endometriosis.

NCT05540353
View directory record Official record
Conditions
Endometriosis, Dyspareunia, Pelvic Pain
Interventions
Transvaginal photobiomodulation, Sham therapy
Device
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Mitchellville, Maryland • Rockville, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Sep 28, 2026, 9:00 PM EDT
Completed Phase 2 Interventional

A Phase II Dose-escalation Study to Assess the Feasibility and Safety of Transendocardial Delivery of Three Different Doses of Allogeneic Mesenchymal Precursor Cells (MPCs)in Subjects With Heart Failure

NCT00721045
View directory record Official record
Conditions
Heart Failure
Interventions
Mesenchymal Precursor Cells (MPCs), standard-of-care treatment with mock mapping and injection procedures.
Biological · Procedure
Lead sponsor
Mesoblast, Ltd.
Industry
Eligibility
20 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
6
States / cities
Gilbert, Arizona • La Jolla, California • Minneapolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Sep 28, 2026, 9:00 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of Epi-on Corneal Cross-linking in Eyes With Progressive Keratoconus

NCT03442751
View directory record Official record
Conditions
Progressive Keratoconus
Interventions
Test Article A, Test Article B, Placebo, KXL medical device system
Drug · Device
Lead sponsor
Glaukos Corporation
Industry
Eligibility
12 Years to 55 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 29, 2024 · Synced Sep 28, 2026, 9:00 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Meaning-Centered Psychotherapy at Home

NCT05495737
View directory record Official record
Conditions
Nurse-Patient Relations, Psychology, Social
Interventions
Meaning-Centered Psychotherapy/MCP-PC Training, Meaning-Centered Psychotherapy/MCP-PC, Treatment As Usual/TAU
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 28, 2026, 9:00 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Effects of Emixustat Hydrochloride in Subjects With Proliferative Diabetic Retinopathy

NCT02753400
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy
Interventions
emixustat hydrochloride, Placebo
Drug · Other
Lead sponsor
Kubota Vision Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Sep 28, 2026, 9:00 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Lesion Progression After Icon Treatment in Young Adults

NCT01988337
View directory record Official record
Conditions
Caries, Salivary Function, Tooth Sensitivity
Interventions
Resin infiltration, Mock treatment
Device · Other
Lead sponsor
DMG Dental Material Gesellschaft mbH
Industry
Eligibility
19 Years and older
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 3, 2022 · Synced Sep 28, 2026, 9:00 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

eHealth Evidence-based Intervention (EBI) for Latino Youth in Primary Care

NCT03009539
View directory record Official record
Conditions
Sexual Risk Behavior, Drug Use, Family Functioning
Interventions
eHealth Familias Unidas Primary Care
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
12 Years to 17 Years
Enrollment
921 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
12
States / cities
Hialeah, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 12, 2024 · Synced Sep 28, 2026, 9:00 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Regularly Transfused, Followed by a 5-Year Extension Period

NCT05144256
View directory record Official record
Conditions
Pediatric Pyruvate Kinase Deficiency, Pediatric Hemolytic Anemia
Interventions
Mitapivat, Mitapivat-matching placebo
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
1 Year to 17 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
9
States / cities
Phoenix, Arizona • Palo Alto, California • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2026 · Synced Sep 28, 2026, 9:00 PM EDT
Terminated Phase 3 Interventional Results available

52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)

NCT02120027
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
Ibodutant 10 mg, Placebo
Drug
Lead sponsor
Menarini Group
Industry
Eligibility
18 Years and older · Female only
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
73
States / cities
Chandler, Arizona • Glendale, Arizona • Mesa, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Sep 28, 2026, 9:00 PM EDT
Completed Phase 3 Interventional Results available

12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)

NCT02107196
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
Ibodutant 10 mg, Placebo
Drug
Lead sponsor
Menarini Group
Industry
Eligibility
18 Years and older · Female only
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
65
States / cities
Huntsville, Alabama • Sherwood, Arizona • Little Rock, Arkansas + 56 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Sep 28, 2026, 9:00 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of MK-1942 as an Adjunct Therapy in Participants With Mild to Moderate Alzheimer's Disease Dementia (MK-1942-008)

NCT05602727
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
MK-1942, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
55 Years to 90 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
22
States / cities
Phoenix, Arizona • Fullerton, California • Sherman Oaks, California + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Sep 28, 2026, 9:00 PM EDT
Completed Not applicable Interventional

Computerized Treatment for Social Anxiety

NCT03101553
View directory record Official record
Conditions
Social Anxiety Disorder
Interventions
Interpretation Bias Modification, Progressive Muscle Relaxation
Behavioral
Lead sponsor
Florida State University
Other
Eligibility
18 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Sep 28, 2026, 9:00 PM EDT
Not listed Not applicable Interventional

Safety and Effectiveness Study of the Zenflow Spring System

NCT04987138
View directory record Official record
Conditions
BPH (Benign Prostatic Hyperplasia), Lower Urinary Tract Symptoms (LUTS)
Interventions
Zenflow Spring System, Sham Procedure
Device
Lead sponsor
Zenflow, Inc.
Industry
Eligibility
45 Years and older · Male only
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
7
States / cities
Los Angeles, California • Glenview, Illinois • Las Vegas, Nevada + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2024 · Synced Sep 28, 2026, 9:00 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Light Emitting Diode-Red Light (LED-RL) Phototherapy for Skin Scarring Prevention

NCT03795116
View directory record Official record
Conditions
Fibrosis, Skin Scarring, Skin Wound, Hypertrophic Scar, Scar, Keloid
Interventions
LED-RL phototherapy, Mock irradiation
Device
Lead sponsor
State University of New York - Downstate Medical Center
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated May 31, 2022 · Synced Sep 28, 2026, 9:00 PM EDT
Not listed Phase 2 Interventional

Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC)

NCT01265576
View directory record Official record
Conditions
HCC
Interventions
Sorafenib, VT-122 (propranolol plus etodolac), Placebo
Drug
Lead sponsor
Vicus Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
10
States / cities
Berkeley, California • Atlanta, Georgia • New Brunswick, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2015 · Synced Sep 28, 2026, 9:00 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Intravitreal Injection of Human Retinal Progenitor Cells in Adults With Retinitis Pigmentosa

NCT03073733
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
human retinal progenitor cells, Mock injection
Biological · Other
Lead sponsor
jCyte, Inc
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Irvine, California • Los Angeles, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 17, 2024 · Synced Sep 28, 2026, 9:00 PM EDT
Completed Phase 3 Interventional Results available

This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder

NCT01972841
View directory record Official record
Conditions
Urinary Bladder Overactive, Urinary Bladder Diseases\Urologic Diseases, Overactive Bladder, Urgency Incontinence
Interventions
Solifenacin succinate, Mirabegron, Placebo to match solifenacin succinate, Placebo to match mirabegron
Drug
Lead sponsor
Astellas Pharma Europe B.V.
Industry
Eligibility
18 Years and older
Enrollment
3,527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
121
States / cities
Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 96 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Sep 28, 2026, 9:00 PM EDT